View source for 18503125. SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER simplified abstract (Board of Regents, The University of Texas System)

=SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER=


==Organization Name==

[[:Category:Board of Regents, The University of Texas System|Board of Regents, The University of Texas System]]


[[Category:Board of Regents, The University of Texas System]]

==Inventor(s)==

[[:Category:Mariano A. Garcia-blanco of Galveston TX (US)|Mariano A. Garcia-blanco of Galveston TX (US)]][[Category:Mariano A. Garcia-blanco of Galveston TX (US)]]

[[:Category:Gaddiel Galarza-munoz of Galveston TX (US)|Gaddiel Galarza-munoz of Galveston TX (US)]][[Category:Gaddiel Galarza-munoz of Galveston TX (US)]]

[[:Category:Shelton S. Bradrick of Galveston TX (US)|Shelton S. Bradrick of Galveston TX (US)]][[Category:Shelton S. Bradrick of Galveston TX (US)]]

==SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18503125 titled 'SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER

==Simplified Explanation==

The present invention involves using an oligonucleotide to target a specific sequence in the Interleukin-7 receptor pre-mRNA to modulate splicing and expression of the soluble isoform of the receptor.

* The method involves administering a composition containing an oligonucleotide that targets a specific sequence in the IL7R pre-mRNA.
* The oligonucleotide can be an antisense oligonucleotide (ASO) or a splice-modulating antisense oligonucleotide (SM-ASO).
* The oligonucleotide influences splicing of exon 6 in IL7R pre-mRNAs, leading to changes in expression of the soluble isoform of IL7R (sIL7R).

== Potential Applications ==
This technology could be applied in the treatment of autoimmune disorders and cancers by modulating the expression of the soluble isoform of the Interleukin-7 receptor.

== Problems Solved ==
This technology addresses the need for more targeted and specific treatments for autoimmune disorders and cancers by modulating the expression of the soluble isoform of the Interleukin-7 receptor.

== Benefits ==
The use of oligonucleotides to modulate splicing of the Interleukin-7 receptor pre-mRNA offers a more precise and targeted approach to treating autoimmune disorders and cancers.

== Potential Commercial Applications ==
Potential commercial applications of this technology could include the development of novel therapeutics for autoimmune disorders and cancers targeting the Interleukin-7 receptor.

== Possible Prior Art ==
One possible prior art in this field is the use of antisense oligonucleotides to modulate gene expression in various diseases. However, the specific targeting of the Interleukin-7 receptor pre-mRNA for splicing modulation may be a novel approach.

=== Unanswered Questions ===

== How does this technology compare to existing treatments for autoimmune disorders and cancers? ==
This article does not provide a direct comparison to existing treatments for autoimmune disorders and cancers. Further research and clinical trials would be needed to determine the efficacy and safety of this technology compared to current standard treatments.

== What are the potential side effects or limitations of using oligonucleotides to modulate splicing in the Interleukin-7 receptor pre-mRNA? ==
The article does not address potential side effects or limitations of this technology. Further studies would be required to assess any adverse effects or challenges associated with using oligonucleotides for splicing modulation in the context of autoimmune disorders and cancers.


==Original Abstract Submitted==

The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).



[[Category:C12N15/113]]
[[Category:A61K31/7088]]
[[Category:A61K45/06]]